$1.03 Billion in Sales Expected for DENTSPLY SIRONA Inc. (NASDAQ:XRAY) This Quarter

Wall Street analysts predict that DENTSPLY SIRONA Inc. (NASDAQ:XRAYGet Rating) will report $1.03 billion in sales for the current fiscal quarter, according to Zacks Investment Research. Eight analysts have made estimates for DENTSPLY SIRONA’s earnings, with estimates ranging from $989.70 million to $1.05 billion. DENTSPLY SIRONA also posted sales of $1.03 billion in the same quarter last year. The company is expected to announce its next earnings report before the market opens on Monday, January 1st.

On average, analysts expect that DENTSPLY SIRONA will report full-year sales of $4.36 billion for the current year, with estimates ranging from $4.31 billion to $4.39 billion. For the next financial year, analysts forecast that the company will post sales of $4.56 billion, with estimates ranging from $4.49 billion to $4.63 billion. Zacks Investment Research’s sales calculations are a mean average based on a survey of research firms that that provide coverage for DENTSPLY SIRONA.

DENTSPLY SIRONA (NASDAQ:XRAYGet Rating) last announced its quarterly earnings results on Monday, February 28th. The medical instruments supplier reported $0.76 EPS for the quarter, missing analysts’ consensus estimates of $0.79 by ($0.03). The business had revenue of $1.09 billion for the quarter, compared to the consensus estimate of $1.13 billion. DENTSPLY SIRONA had a return on equity of 12.51% and a net margin of 9.90%. The firm’s revenue for the quarter was up .6% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.87 EPS.

A number of research analysts have commented on XRAY shares. Barrington Research cut their price target on shares of DENTSPLY SIRONA from $79.00 to $72.00 in a research note on Tuesday, March 1st. The Goldman Sachs Group cut their price target on shares of DENTSPLY SIRONA from $66.00 to $59.00 and set a “neutral” rating for the company in a research note on Tuesday, March 1st. Credit Suisse Group cut their target price on shares of DENTSPLY SIRONA from $68.00 to $67.00 and set an “outperform” rating for the company in a research note on Tuesday, March 1st. HC Wainwright cut their target price on shares of DENTSPLY SIRONA from $66.00 to $58.00 in a research note on Tuesday, March 1st. Finally, TheStreet cut shares of DENTSPLY SIRONA from a “b-” rating to a “c+” rating in a research note on Friday, March 18th. Two research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $66.00.

Several institutional investors have recently modified their holdings of XRAY. First Trust Advisors LP grew its holdings in DENTSPLY SIRONA by 203.9% during the 1st quarter. First Trust Advisors LP now owns 91,083 shares of the medical instruments supplier’s stock worth $4,517,000 after acquiring an additional 61,111 shares during the period. Amundi Pioneer Asset Management Inc. grew its holdings in shares of DENTSPLY SIRONA by 39.9% in the 1st quarter. Amundi Pioneer Asset Management Inc. now owns 184,628 shares of the medical instruments supplier’s stock valued at $9,157,000 after buying an additional 52,645 shares during the period. Morgan Stanley grew its holdings in shares of DENTSPLY SIRONA by 16.1% in the 2nd quarter. Morgan Stanley now owns 607,754 shares of the medical instruments supplier’s stock valued at $38,445,000 after buying an additional 84,088 shares during the period. Crossmark Global Holdings Inc. grew its holdings in shares of DENTSPLY SIRONA by 1.5% in the 3rd quarter. Crossmark Global Holdings Inc. now owns 16,878 shares of the medical instruments supplier’s stock valued at $980,000 after buying an additional 243 shares during the period. Finally, Park Avenue Securities LLC grew its holdings in shares of DENTSPLY SIRONA by 4.6% in the 3rd quarter. Park Avenue Securities LLC now owns 4,380 shares of the medical instruments supplier’s stock valued at $254,000 after buying an additional 194 shares during the period. 97.32% of the stock is owned by institutional investors and hedge funds.

XRAY traded up $0.32 during midday trading on Tuesday, reaching $49.07. 887,750 shares of the company’s stock were exchanged, compared to its average volume of 1,872,640. The firm has a market capitalization of $10.57 billion, a price-to-earnings ratio of 25.56, a price-to-earnings-growth ratio of 1.57 and a beta of 0.86. The company has a quick ratio of 1.12, a current ratio of 1.55 and a debt-to-equity ratio of 0.38. DENTSPLY SIRONA has a one year low of $47.06 and a one year high of $69.54. The business has a 50-day simple moving average of $51.28 and a two-hundred day simple moving average of $53.53.

The business also recently declared a quarterly dividend, which was paid on Friday, April 8th. Investors of record on Friday, March 25th were issued a $0.125 dividend. The ex-dividend date of this dividend was Thursday, March 24th. This represents a $0.50 dividend on an annualized basis and a dividend yield of 1.02%. This is a positive change from DENTSPLY SIRONA’s previous quarterly dividend of $0.11. DENTSPLY SIRONA’s dividend payout ratio (DPR) is currently 26.04%.

DENTSPLY SIRONA Company Profile (Get Rating)

DENTSPLY SIRONA Inc designs, develops, manufactures, distributes, and sells various dental products and technologies for professional dental market worldwide. It offers dental equipment, including treatment centers, imaging equipment, motorized dental handpieces, and other instruments; imaging equipment; treatment centers comprising basic dentist chairs, sophisticated chair-based units with integrated diagnostic, hygiene and ergonomic functionalities, and specialist centers; and lab equipment, such as amalgamators, mixing machines, and porcelain furnaces.

Featured Stories

Get a free copy of the Zacks research report on DENTSPLY SIRONA (XRAY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for DENTSPLY SIRONA (NASDAQ:XRAY)

Receive News & Ratings for DENTSPLY SIRONA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA and related companies with MarketBeat.com's FREE daily email newsletter.

$1.03 Billion in Sales Expected for DENTSPLY SIRONA Inc. (NASDAQ:XRAY) This Quarter

Wall Street brokerages expect that DENTSPLY SIRONA Inc. (NASDAQ:XRAYGet Rating) will announce sales of $1.03 billion for the current fiscal quarter, according to Zacks. Eight analysts have provided estimates for DENTSPLY SIRONA’s earnings. The lowest sales estimate is $989.70 million and the highest is $1.05 billion. DENTSPLY SIRONA also posted sales of $1.03 billion during the same quarter last year. The firm is scheduled to announce its next earnings results before the market opens on Monday, January 1st.

On average, analysts expect that DENTSPLY SIRONA will report full-year sales of $4.36 billion for the current financial year, with estimates ranging from $4.31 billion to $4.39 billion. For the next fiscal year, analysts expect that the company will post sales of $4.56 billion, with estimates ranging from $4.49 billion to $4.63 billion. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research analysts that cover DENTSPLY SIRONA.

DENTSPLY SIRONA (NASDAQ:XRAYGet Rating) last announced its quarterly earnings data on Monday, February 28th. The medical instruments supplier reported $0.76 earnings per share for the quarter, missing analysts’ consensus estimates of $0.79 by ($0.03). DENTSPLY SIRONA had a return on equity of 12.51% and a net margin of 9.90%. The firm had revenue of $1.09 billion during the quarter, compared to analysts’ expectations of $1.13 billion. During the same quarter in the previous year, the firm earned $0.87 earnings per share. DENTSPLY SIRONA’s revenue was up .6% on a year-over-year basis.

XRAY has been the subject of a number of recent analyst reports. Barrington Research decreased their price objective on shares of DENTSPLY SIRONA from $79.00 to $72.00 in a report on Tuesday, March 1st. StockNews.com started coverage on shares of DENTSPLY SIRONA in a report on Thursday, March 31st. They issued a “buy” rating for the company. Robert W. Baird decreased their target price on shares of DENTSPLY SIRONA from $78.00 to $67.00 and set an “outperform” rating for the company in a research note on Friday, February 18th. Credit Suisse Group decreased their target price on shares of DENTSPLY SIRONA from $68.00 to $67.00 and set an “outperform” rating for the company in a research note on Tuesday, March 1st. Finally, HC Wainwright decreased their target price on shares of DENTSPLY SIRONA from $66.00 to $58.00 in a research note on Tuesday, March 1st. Two analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $66.00.

NASDAQ XRAY traded up $0.32 during mid-day trading on Tuesday, reaching $49.07. The stock had a trading volume of 887,750 shares, compared to its average volume of 1,872,640. DENTSPLY SIRONA has a 1 year low of $47.06 and a 1 year high of $69.54. The stock has a market cap of $10.57 billion, a PE ratio of 25.56, a price-to-earnings-growth ratio of 1.57 and a beta of 0.86. The company has a fifty day moving average price of $51.28 and a 200 day moving average price of $53.53. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.55 and a quick ratio of 1.12.

The business also recently disclosed a quarterly dividend, which was paid on Friday, April 8th. Stockholders of record on Friday, March 25th were paid a $0.125 dividend. This represents a $0.50 annualized dividend and a dividend yield of 1.02%. This is a positive change from DENTSPLY SIRONA’s previous quarterly dividend of $0.11. The ex-dividend date was Thursday, March 24th. DENTSPLY SIRONA’s dividend payout ratio is 26.04%.

Large investors have recently bought and sold shares of the company. Geode Capital Management LLC increased its stake in shares of DENTSPLY SIRONA by 2.8% in the 3rd quarter. Geode Capital Management LLC now owns 4,061,180 shares of the medical instruments supplier’s stock worth $235,146,000 after purchasing an additional 109,108 shares in the last quarter. Invesco Ltd. increased its stake in shares of DENTSPLY SIRONA by 12.9% in the 3rd quarter. Invesco Ltd. now owns 3,969,998 shares of the medical instruments supplier’s stock worth $230,459,000 after purchasing an additional 454,358 shares in the last quarter. Gabelli Funds LLC increased its stake in shares of DENTSPLY SIRONA by 118.8% in the 3rd quarter. Gabelli Funds LLC now owns 151,000 shares of the medical instruments supplier’s stock worth $8,766,000 after purchasing an additional 82,000 shares in the last quarter. Ensign Peak Advisors Inc increased its stake in shares of DENTSPLY SIRONA by 27.8% in the 3rd quarter. Ensign Peak Advisors Inc now owns 45,684 shares of the medical instruments supplier’s stock worth $2,652,000 after purchasing an additional 9,934 shares in the last quarter. Finally, Fifth Third Bancorp increased its stake in shares of DENTSPLY SIRONA by 0.7% in the 4th quarter. Fifth Third Bancorp now owns 31,816 shares of the medical instruments supplier’s stock worth $1,775,000 after purchasing an additional 222 shares in the last quarter. Hedge funds and other institutional investors own 97.32% of the company’s stock.

About DENTSPLY SIRONA (Get Rating)

DENTSPLY SIRONA Inc designs, develops, manufactures, distributes, and sells various dental products and technologies for professional dental market worldwide. It offers dental equipment, including treatment centers, imaging equipment, motorized dental handpieces, and other instruments; imaging equipment; treatment centers comprising basic dentist chairs, sophisticated chair-based units with integrated diagnostic, hygiene and ergonomic functionalities, and specialist centers; and lab equipment, such as amalgamators, mixing machines, and porcelain furnaces.

Featured Stories

Get a free copy of the Zacks research report on DENTSPLY SIRONA (XRAY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for DENTSPLY SIRONA (NASDAQ:XRAY)

Receive News & Ratings for DENTSPLY SIRONA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA and related companies with MarketBeat.com's FREE daily email newsletter.